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Key Points 
1. Mutant CALR drives ET and MF in knock-in mice 




Somatic mutations in the endoplasmic reticulum chaperone calreticulin (CALR) are detected in 
approximately 40% of patients with essential thrombocythemia (ET) and primary myelofibrosis 
(PMF).  Multiple different mutations have been reported, but all result in a +1bp frame shift and 
generate a novel protein C-terminus.  In this study, we generated a conditional mouse knock-in 
model of the most common CALR mutation, a 52bp deletion.  The mutant novel human C-terminal 
sequence is integrated into the otherwise intact mouse CALR gene and results in mutant CALR 
expression under the control of the endogenous mouse locus.  CALRdel/+ mice develop a 
transplantable ET-like disease with marked thrombocytosis associated with increased and 
morphologically abnormal megakaryocytes and increased numbers of phenotypically-defined 
hematopoietic stem cells (HSCs).  Homozygous CALRdel/del mice developed extreme 
thrombocytosis accompanied by features of myelofibrosis including leukocytosis, reduced 
hematocrit, splenomegaly and increased bone marrow reticulin.  CALRdel/+ HSCs were more 
proliferative in vitro, but neither CALRdel/+ nor CALRdel/del displayed a competitive transplantation 
advantage in primary or secondary recipient mice.  These results demonstrate the consequences of 
heterozygous and homozygous CALR mutations and provide a powerful model for dissecting the 
pathogenesis of CALR-mutant ET and PMF. 
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INTRODUCTION 
The myeloproliferative neoplasms (MPNs) are chronic hematological malignancies that arise in 
the hematopoietic stem cell (HSC) compartment and share a variable propensity to transform to 
acute myeloid leukemia.1-3  The BCR-ABL-negative ‘classic’ MPNs are described as falling into 
three categories: polycythemia vera (PV), essential thrombocythemia (ET) and primary 
myelofibrosis (PMF).  PV and ET are chronic phase disorders with a relatively benign prognosis 
– major complications include thrombosis and myelofibrotic transformation. PMF is less common 
and is a more advanced disease. It closely resembles myelofibrotic transformation of PV and ET, 
and in many cases is likely to represent presentation in accelerated phase of an undiagnosed pre-
existing ET.4,5 
 
Most patients with one of the three classical MPNs harbor phenotypic driver mutations that affect 
cytokine signaling through JAK family kinases.6  The most common lesion is an acquired 
JAK2V617F mutation.7-10  With the subsequent discovery of JAK2 exon 12 mutations, it is now 
clear that the vast majority of PV patients harbor a gain-of-function mutation in JAK2.11  In ET 
and PMF, only 50% of patients carry a JAK2 mutation.  Of the JAK2 non-mutated patients, 
approximately 5-10% carry a gain-of-function mutation in THPO receptor (MPL), the gene for the 
thrombopoietin (THPO) receptor12, and a further 70-84% possess mutations in CALR, which 
encodes an endoplasmic reticulum chaperone.6,13  
 
Though multiple different CALR mutations have been described,2,6,13 all are deletions or insertions 
within exon 9 that results in a +1bp frame shift and thereby generate a protein with a novel C-
terminus. Recent structure/function studies have elegantly shown that mutant CALR interacts with 
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the extracellular domain of THPO receptor to activate downstream signaling and that the novel C-
terminus is essential for this process.14-16   Retroviral studies14,17 and transgenic studies18 (in which 
mutant CALR cDNA was driven by the H-2Kb promoter and Mo-MuLV LTR) have shown that 
mutant CALR can generate a myeloproliferative phenotype in mice.  However, the pathogenetic 
consequences of expressing mutant CALR in an appropriate cell type-specific manner and at 
physiological levels are unknown.  Here, we describe the generation of knock-in mice expressing 
the most common form of mutant CALR (52bp deletion) under the control of the mouse CALR 
locus.   
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MATERIALS AND METHODS 
Generation of hematopoietic-specific conditional knock-in mice for mutant calreticulin 
A 9.3 kb region spanning exons 2-9 of mouse CALR (corresponding to nucleotides 16143-25460 
in the reverse complementary sequence of the mouse BAC clone RP24-341A18, accession number 
AC155163) was manipulated to include the targeting cassettes.  A LoxP site was inserted into 
nucleotide position 19478 of the 5’ homology arm (nucleotides 16143-20881) which was followed 
downstream by a PGKNeo-poly(A) minigene and another LoxP site.  The 3’ homology arm 
(20141-25460) is preceded by sequence (19499-10782) including part of the mouse intron 7 and 
of exon 8, which was fused at the BsmBI site with the mutant human CALR cDNA sequence 
(corresponding to nucleotides 1095-1350, accession number BC020493).  A thymidine kinase 
(TK) minigene located downstream of the 3’ homology arm was also included in the targeting 
vector.  The targeting plasmid DNA linearized with NotI was used for gene targeting in embryonic 
stem cells (ES cells, JM8 in C57BL/6N background) and ES clones resistant to G418 and FIAU 
were selected.  ES clones with correctly targeted alleles (designated CALRfl/+) were injected into 
albino C57BL/6 blastocysts and chimeras were bred with C57BL/6 mice to generate germline 
heterozygous CALRfl/+ mice.  All mice were kept in specific pathogen free conditions and all 
procedures performed according to UK Home Office regulations. 
 
Bone marrow transplantation assays 
For transplantation assays, KitW41/W41 (CD45.1) recipients were irradiated with 400 cGy and 
C57BL/6 (CD45.1) recipients were irradiated with 2 x 550 cGy.  The KitW41/W41 strain is derived 
from C57BL/6 which requires only a sub-lethal dose of radiation and is more permissive for donor 
cell engraftment since the endogenous HSCs are >10-fold less functional.  For non-competitive 
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transplantation assays, 2 x 106 nucleated BM cells were injected into recipient mice.  Peripheral 
blood was obtained every four weeks when full blood counts were determined and donor cell 
repopulation was examined by flow cytometric analysis using CD45.1 and CD45.2 antibodies (BD 
Biosciences).  For competitive repopulation assays, 1 x 106 nucleated competitor BM cells (a 1:1 
ratio) were obtained from CD45.1/CD45.2 F1 mice and injected into recipient mice. For secondary 
BM transplantation, 5 x 106 nucleated BM cells from primary recipients were injected into 
recipient mice.  In all cases, peripheral blood was obtained and analyzed by flow cytometry for 
donor contribution to myeloid (Ly6g and Mac1) and lymphoid (B220 and CD3e) cells. 
 
Single HSC in vitro Cultures 
In vitro culture of single E-SLAM HSCs was performed as previously described.19,20  E-SLAM 
HSCs were sorted into round-bottom 96-well plates, preloaded with 50 µL serum-free Stemspan 
medium (STEMCELL Technologies). A further 50 µL of medium was subsequently added to each 
well to a final concentration of 10% FCS, 1% Pen/Strep, 1% L-Glut, 300 ng/mL SCF 
(STEMCELL Technologies), 20 ng/mL IL-11 (STEMCELL Technologies) and 0.1 mM β-
mercaptoethanol.  For cell division kinetics, the number of cells in each well was counted manually 
every day for up to 4 days in culture.  To evaluate the number and proportion of mature cell types 
produced by single E-SLAM HSCs in vitro, after 7 days in culture, clonal cells were stained with 
antibodies for lineage markers (CD3, Ly6G/Ly6C, CD11b, CD45R/B220, Ter-119), Sca-1 BV605 
and c-Kit APC/Cy7 to assess the frequencies of LSK (Lineage-Sca-1+c-Kit+) and lineage positive 
cells.  Lineage output of single cell cultures was also analyzed after 14 days using flow cytometry 
with antibodies for Mac1 APC, CD41 PE, and CD71 FITC. 
Statistics 
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The statistical differences between control and CALRdel/+ mice were assessed using a two-tailed, 
unpaired Student’s t-test unless otherwise indicated. 
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RESULTS 
Generation of conditional mutant calreticulin knock-in mice  
To study the role of calreticulin mutations in the pathogenesis of MPNs, we generated a conditional 
knock-in allele in murine ES cells using homologous recombination for the most common CALR 
mutation (52 bp deletion) (Figure 1A).  Species-specific differences in codon preferences meant 
that simply generating an analogous 52bp deletion within the mouse sequence would generate a 
novel C-terminus substantially different from that seen in ET patients (Figure 1B).  We therefore 
adopted a strategy in which the targeted allele (CALRfl) contains a LoxP site in intron 7, and a 
PGKNeo-polyA LoxP cassette followed by mouse exon 8 fused with mutant human calreticulin 
3’ cDNA sequence downstream of exon 9 (Figure 1A; supplemental Figure 1A).  This approach 
allowed the generation of a conditional allele expressing a mutant calreticulin protein with a 
carboxy‐terminal amino acid sequence identical to that found in MPN patients, whilst keeping the 
mouse sequence otherwise intact (Figure 1B).  The targeted allele (CALRfl) is predicted to express 
wild-type mouse calreticulin and can be induced to express humanized mutant calreticulin under 
the control of murine CALR regulatory elements upon removal of the floxed mouse CALR exons 
and PGKNeo-polyA by Cre-mediated recombination. Correctly targeted ES clones were 
characterized by genomic PCR (Figure 1C, 1D; supplemental Figure 1B).  Targeted ES clones 
were expanded and then subjected to transient Cre expression using a PGK-Cre plasmid.  Genomic 
PCR confirmed the recombination of the allele (Figure 1E).  RT-PCR was performed on total RNA 
from ES cells after Cre recombination and the PCR product was cloned and sequenced to 
demonstrate expression of CALR mRNA with the 52bp deletion (Figure 1F; supplemental Figure 
1C).  Correctly targeted ES cells were then injected into C57BL/6 albino blastocysts to produce 
chimeras.  The resulting chimeric mice were bred to C57BL/6 mice to generate germline 
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transmission (i. e. CALRfl/+ mice).  Quantitative RT-PCR demonstrated that CALRfl/+ mice 
expressed levels of CALR comparable with CALR+/+ mice (supplemental Figure 1D). 
 
CALRdel/+ mice develop a myeloproliferative phenotype resembling human essential 
thrombocythaemia   
CALRfl/+ mice were crossed with Mx1Cre transgenic mice21 and expression of Cre recombinase 
was induced with polyinosine-polycytosine (pIpC) injection 6-8 weeks after birth.  Mice carrying 
the recombined allele with mutant calreticulin expression were denoted CALRdel/+.   Without pIpC 
treatment, recombination did not occur at detectable levels and blood counts were normal in 
Mx1Cre positive CALRfl/+ mice (supplemental Figures 2A, B).  By 4 weeks after pIpC, genomic 
PCR showed recombination in more than 80% of nucleated blood cells (supplemental Figure 2C).  
Mutant CALR RNA expression was confirmed by RT-PCR in bone marrow cells (supplemental 
Figure 2D).  In HSPCs, transcript levels of mutant CALR were 65-72% (mean 68%) of transcript 
levels from the WT allele as analysed by fragment analysis (Supplemental Figure 2E). A reduction 
in the level of mutant transcripts was also seen using several different expression constructs 
(supplemental Figure 2F) and in a previously reported transgenic model,18  indicating that lower 
levels of mutant CALR transcripts are not specific to the targeting construct used to generate our 
knock-in mice, and may instead reflect altered stability associated with the novel 3’ sequence.  
Levels of the mutant protein in CALRdel/del mice were much lower than levels of WT protein in 
control cells (supplemental Figure 2G), an observation consistent with the previous demonstration 
that the mutant protein is unstable51,52 and also consistent with the results from a retroviral 
transplantation model.17 
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CALRdel/+ mice developed a striking thrombocytosis compared with wild-type littermate controls.  
White blood cell (WBC) counts were mildly elevated in some but not all cohorts, and red blood 
cell (RBC) parameters were not affected (Figure 2A).  No difference in survival was observed in 
cohorts maintained for up to 8 months (supplemental Figure 3A).  We also crossed CALRfl/+ mice 
with VavCre transgenic mice22.  Similar to results with Mx1Cre, VavCre resulted in high rates of 
recombination in peripheral blood and mice developed thrombocytosis (supplemental Figure 3B 
and C).   
 
In JAK2V617F knock-in mice, platelet reactivity to collage-related peptide (CRP) and 
thrombin agonists was increased.23  We therefore studied platelet reactivity to several agonists 
including CRP, thrombin and ADP, but observed no significant increase in response to any agonist 
using platelets of the CALRdel/+ mice (supplemental Figure 3D). 
 
Bone marrow cellularity and spleen weight were not significantly affected in CALRdel/+ mice 3-4 
months after pIpC injection (supplemental Figure 4A and B).  Histological analysis of BM from 
CALRdel/+ mice showed megakaryocytic hyperplasia with megakaryocytes displaying large and 
hyperlobated nuclei and increased clustering (Figure 2B).  Spleen architecture was not affected, 
although a degree of extra-medullary hematopoiesis was observed in some cases, and there was 
no significant increase in reticulin staining in either bone marrow or spleen at this time point 
(Figure 2B; supplemental Figure 4C).  Compared to littermate controls, the bone marrow of 
CALRdel/+ mice contained increased numbers of CFU-MKs (Figure 2C) and megakaryocytes 
(Figure 2D) together with reduced numbers of CD71+Ter119+ erythroblasts (Figure 2E).  Numbers 
of myeloerythroid progenitor populations and more mature myeloid cells (Mac1+Ly6g+) in the 
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bone marrow were not significantly altered (supplemental Figure 4D).  In the spleen, there was no 
significant alteration in the proportion of megakaryocytes, myeloid cells or erythroblasts 
(supplemental Figure 4E).  Taken together, these data demonstrate that CALRdel/+ mice displayed 
a marked thrombocytosis accompanied by increased megakaryopoiesis and compromised 
erythropoiesis in the bone marrow. 
 
Thrombocytosis in CALRdel/+ mice is transplantable 
Thrombopoietin (THPO) levels were not raised in CALRdel/+ mice and were, if anything, reduced 
(although this did not reach statistical significance), suggesting that the thrombocytosis was not 
THPO-driven and was likely to be cell-intrinsic (Figure 3A).  To confirm this inference, wild-type 
recipient mice were transplanted with bone marrow cells from CALRdel/+ mice 2 months post pIpC.  
At both one month and four months after transplant, the level of chimerism was approximately 
80% in peripheral blood mononuclear cells, myeloid cells (Ly6g+ and Mac1+) and lymphoid cells 
(B220+ and CD3e+) (Figure 3B; supplemental  Figure 5A).  Recipients of CALRdel/+ bone marrow 
developed marked thrombocytosis with platelet numbers similar to donor mice by 4 months post-
transplantation (Figure 3C).  Following secondary transplants, recipients also developed 
thrombocytosis (Figure 3D) with donor chimerism at 4 months post transplantation around 60% 
for peripheral blood mononuclear cells, myeloid cells and lymphoid cells (Figure 3E, supplemental 
Figure 5B) indicating that thrombocytosis was still evident in the presence of 40% normal 
hematopoietic cells.  These data demonstrate that the thrombocytosis in CALRdel/+ mice is 
transplantable and reflects a bone marrow-cell intrinsic mechanism.  
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Mutant CALR is associated with increased proliferation of single HSCs in vitro but no self-
renewal advantage in vivo 
The bone marrow of CALRdel/+ mice contained increased numbers of HSCs, both Lin-
Sca1+cKit+CD150+CD48- HSCs (Figure 4A) and E-SLAM HSCs (CD45+EPCR+CD150+CD48-, 
supplemental Figure 6A).  To examine the effect of mutant CALR on the behaviour of HSCs, we 
studied the survival and cell division kinetics of single HSCs together with their ability to 
proliferate and differentiate.19,20  Compared to wildtype controls, the proportion of single 
CALRdel/+ HSCs that gave rise to clones of over 50 cells after 7 days in culture was significantly 
higher (Figure 4B). Single HSCs from CALRdel/+ mice showed significantly earlier cell division 
compared with those from littermate controls (Figure 4C) and formed larger clones after 7 days in 
culture (Figure 4D, supplemental Figure 6B).  Although clones from CALRdel/+ HSCs were larger, 
flow cytometric analysis showed that they contained unaltered percentages of LSK cells, lineage 
positive, Mac1+, CD41+ and CD71+ cells (supplemental Figure 6C-E).  
 
To investigate the functional consequences of mutant calreticulin on HSCs, competitive bone 
marrow transplantation was performed using cells from mice at 2 months after pIpC.  Bone marrow 
cells from CALRdel/+ or littermate control mice (both CD45.2) were mixed with equal numbers of 
CD45.1/45.2 F1 competitor bone marrow cells and transplanted into irradiated C57Bl/6 recipients 
(CD45.1).  The contribution of CALRdel/+ cells to recipient peripheral blood, myeloid cells (Ly6g+ 
and Mac1+) and lymphoid cells (B220+ and CD3e+) was similar to littermate controls at both 1 and 
4 months following transplantation (Figure 4E).   Recipients of CALRdel/+ bone marrow did not 
develop thrombocytosis (supplemental Figure 6F); probably because donor chimerism was usually 
lower than 50% in this setting.  Analysis of the recipient bone marrow 4 months after transplant 
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revealed a similar picture.  Compared to control cells, CALRdel/+ cells showed no increase in their 
contribution to E-SLAM HSCs (Figure 4F), myeloid and lymphoid lineages (Figure 4G).  
Secondary transplants were performed, and at 4 months after transplantation, CALRdel/+ cells again 
showed no significant repopulation advantage (Figure 4H).  Together, these data show that 
CALRdel/+ bone marrow contains more phenotypically defined HSCs, and these cells exhibit 
increased proliferation in vitro, but the long term in vivo repopulating activity of CALRdel/+ bone 
marrow is normal. 
 
Homozygosity for CALR mutation (CALRdel/del) results in severe thrombocytosis and 
development of myelofibrosis  
To assess the pathological consequences of homozygous expression of mutant calreticulin, 
CALRfl/+ mice on an Mx1Cre background were crossed with each other to generate CALRfl/fl mice.  
Upon Cre recombination, mice with homozygous expression of mutant calreticulin (denoted as 
CALRdel/del) developed extreme thrombocytosis with platelet counts around 9x 106/uL by 3-4 
months after pIpC (Figure 5A).  This was accompanied by a modest but significant increase in 
WBC numbers and reduced hematocrit (Figure 5A).  By 6-8 months post pIpC, CALRdel/del mice 
showed splenomegaly (Figure 5B, supplemental Figure 7A) and reduced bone marrow cellularity 
(supplemental Figure 7B).  Macroscopically, bone marrow samples from the CALRdel/del were 
paler and their spleen cell samples were redder in colour compared with the littermate controls 
(supplemental Figure 7C).  Histological analysis of bone marrow showed almost complete 
effacement of normal hematopoiesis by megakaryocytes displaying nuclear atypia and 
accompanied by increased levels of reticulin (Figure 5C, supplemental Figure 7D).  H&E staining 
of sections of the spleen showed destruction of normal splenic architecture with markedly 
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increased numbers of atypical megakaryocytes without increased levels of reticulin (Figure 5C, 
supplemental Figure 7E).  
 
Flow cytometric analysis demonstrated that CALRdel/del bone marrow harboured substantially 
increased numbers of HSCs, both Lin-Sca1+cKit+CD150+CD48- HSCs (Figure 5D) and E-SLAM 
HSCs (supplemental Figure 7F).  Marked increases in the proportion of megakaryocyte 
progenitors (MkP, Lin-Sca1-cKit+CD150+CD41+) were noted in both bone marrow and spleen 
(Figures 5E).  Myeloid progenitors (Lin-Sca1-cKit+), PreGM (Lin-Sca1-cKit+CD41-CD16/32-
CD105-CD150-) and GMP (Lin-Sca1-cKit+CD41-CD16/32+CD150-) were expanded in CALRdel/del 
mice (Figure 5F; supplemental Figure 7G), and erythroblasts (CD71+Ter119+) were reduced in 
bone marrow but erythroid progenitors (PreCFU-E, Lin-Sca1-cKit+CD41-CD16/32-
CD105+CD150+) were increased in the spleen (Figure 5G; supplemental Figure 7G). Taken 
together, these data demonstrate that homozygosity for mutant CALR produces a dramatic 
phenotype with extreme thrombocytosis, a marked increase in megakaryopoiesis, myelofibrosis 
and HSC expansion.  
 
Non-competitive bone marrow transplants were performed to see if this extreme thrombocytosis 
is transplantable.  Wild-type recipient mice were transplanted with bone marrow cells from 
CALRdel/del mice.  At 4 months after transplant, the level of chimerism was approximately 70% in 
peripheral blood mononuclear cells, myeloid cells (Ly6g+ and Mac1+) and lymphoid cells (B220+ 
and CD3e+) (Figure 6A).  Recipients of CALRdel/del bone marrow developed a similar degree of 
thrombocytosis with platelet numbers similar to the CALRdel/del donor mice by 5 months post-
transplantation as well as leukocytosis (Figure 6A).  These data demonstrate that the extreme 
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thrombocytosis in CALRdel/del mice is transplantable.  To investigate the functional consequences 
of mutant calreticulin homozygosity on HSCs, competitive bone marrow transplantation was 
performed.  Bone marrow cells from CALRdel/del or littermate control mice (both CD45.2) were 
mixed with equal numbers of CD45.1/45.2 F1 competitor bone marrow cells and transplanted into 
irradiated KitW41/W41 C57Bl/6 recipients (CD45.1).  The contribution of CALRdel/del cells to 
recipient peripheral blood, myeloid cells (Ly6g+ and Mac1+) and lymphoid cells (B220+ and 
CD3e+)  was analysed by flow cytometry and was similar to littermate controls (Figure 6B).   At 
4 months post transplantation, secondary transplants were performed, analysis showed that 
CALRdel/del cells exhibit similar competitive repopulating capacity in the secondary recipients 
(Figure 6C).  Together, these data demonstrate that CALRdel/del bone marrow contains strikingly 
expanded phenotypically defined HSCs, but the long term in vivo repopulating activity of 









In this paper, we describe a knock-in mouse model of the most common CALR mutation, an 
approach that allows us to explore the consequences of mutant CALR without the confounding 
effects of additional mutations present in samples from MPN patients.  The targeting strategy was 
chosen to result in expression of a murine CALR protein in which the wild type C-terminus is 
replaced by the mutant human C-terminus found in MPN patients.  Following Cre-mediated 
recombination, the mutant transcript is expressed under the control of the full complement of 
endogenous CALR regulatory elements.   
  
Heterozygous CALRdel/+ mice develop an ET-like phenotype with marked thrombocytosis, 
increased megakaryopoiesis and abnormal bone marrow megakaryocyte morphology.   
Hemoglobin and red cell levels were normal and there was no increased reticulin staining in the 
bone marrow.  The results contrast with the phenotype of JAK2V617F knock-in mice in which 
platelets, hemoglobin and leukocytes are all elevated and the bone marrow contains increased 
erythroid, myeloid and megakaryocytic progenitors.24-27  Moreover, these differing phenotypes are 
consistent with what is observed in JAK2-mutant compared to CALR-mutant MPN patients.  The 
isolated thrombocytosis seen in CALRdel/+ mice resembles that seen in CALR-mutant ET patients 
and, compared to JAK2-mutant ET patients, those carrying a CALR mutation have higher platelet 
levels with lower levels of hemoglobin and white cells.28-31   Furthermore, the effect of mutant 
CALR on platelet reactivity was different from that previously observed with JAK2 mutant cells.23  
Whilst the former showed normal responses to platelet agonists, JAK2 mutant platelets were 
hyper-reactive. These results are in keeping with the increased thrombosis rate observed in patients 
bearing JAK2 mutations.30  
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Homozygosity for CALR mutations has been observed in patients with ET,13,31,32 but its 
pathogenetic consequences are unclear.  Our results demonstrate that homozygosity for mutant 
CALR causes extreme thrombocytosis associated with increased white cell counts, reduced 
hemoglobin levels, splenomegaly and increased levels of bone marrow reticulin, a constellation of 
features that resemble myelofibrotic transformation of ET.  This phenotype contrasts with that 
seen in mice homozygous for JAK2V617F, which show extreme elevation of hemoglobin levels 
and a fall in platelet counts relative to mice heterozygous for JAK2V617F.33  Together, our data 
demonstrate clear differences in the consequences of CALR and JAK2 mutations, and that these 
differences are more pronounced in the homozygous setting.  
 
Our results accord with observations made using retroviral transplants or transgenic mice 
expressing the human mutant CALR.14,17,18  Both approaches resulted in thrombocytosis and 
megakaryocytic hyperplasia, but myelofibrosis was only seen in mice harboring retroviral 
constructs,17 perhaps reflecting varying levels of expression achieved by these different 
approaches.  This concept is consistent with our finding of myelofibrosis is in CALRdel/del but not 
in CALRdel/+ mice.   
 
Our results shed light on the role of mutant CALR within the HSC compartment. Bone marrow 
transplant studies demonstrated that the ET-like phenotype seen in CALRdel/+ mice could be 
propagated in both primary and secondary recipients.  These results demonstrate that CALR-
mutant long-term repopulating HSCs are able to give rise to features of ET even in secondary 
recipients where chimerism levels were reduced to 60%.  These observations accord with studies 
of patients with CALR-mutant ET, which showed that the CALR mutation is present in highly 
 18 
purified HSCs.6  Moreover, analyses of individual hematopoietic colonies showed that the CALR 
mutation was present in the first mutant phylogenetic node in all 5 patients studied, indicating that 
it was likely to be an initiating mutation in these patients.6   
 
However, our data show that mutant CALR does not confer a competitive HSC advantage in serial 
transplants in either heterozygous or homozygous settings. This result is consistent with the report 
of a transgenic mouse model which concluded that HSCs expressing mutant CALR exhibited 
normal self-renewal.18  In a retroviral transplant model, phenotypic GFP+ LSK and GFP+ SLAM 
LSK cells expanded over time in primary recipient mice.17  However, secondary transplants were 
not performed and therefore the impact on long term HSC function remains unclear.  Both 
transgenic and retroviral approaches are known to result in dysregulated expression, both in terms 
of transcript levels and pattern of expression, which may contribute to the distinct phenotypes. 
 
It is interesting that our knock-in mutant CALR mice (and three independent mutant JAK2 knock-
in mice20,24,34,35) all show no HSC advantage in serial transplantation studies, despite mutant CALR 
(or mutant JAK2) being found as a sole driver mutation in a substantial proportion of MPN 
patients.  There are several potential explanations (not mutually exclusive) for this apparent 
conundrum: (i) genetic background may cooperate with mutant CALR — there is mounting 
evidence that genetic background influences HSC function in mice36,37 and also the development 
of both MPNs38-40 and clonal hematopoiesis41;  (ii) unidentified somatic driver mutations may 
cooperate with mutant CALR — it seems unlikely that many additional coding mutations remain 
to be discovered, but there is much less known about the role of somatic non-coding mutations 
affecting regulatory elements in tumors42-44;  (iii) age-related changes affecting the 
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microenvironment (eg niche or inflammatory signaling) may explain the association of MPNs with 
increasing age45-47; and (iv) lineage tracing studies suggest that steady state hematopoiesis is 
supported by long-lived progenitors that may not read out in transplantation assays.48,49  
 
Levels of the mutant protein were much lower than levels of WT protein, consistent with previous 
findings that the mutant protein is unstable50,51 and less abundant compared to WT controls in a 
retroviral expression model.17  We also noted that, in HSPCs from heterozygous knock-in mice, 
mutant transcripts were expressed at lower levels (mean 68%) relative to WT transcripts.  We 
considered the possibility that this might reflect a technical problem with our construct and explain 
the lack of a clonal advantage.  Although our data do not formally exclude this scenario, we believe 
this is highly unlikely for multiple reasons: (1) The knock-in construct gives rise to strong HSC, 
progenitor, megakaryocytic and platelet phenotypes. HSC, progenitor and platelet numbers are 
similar to or higher than those seen in the retroviral or transgenic mouse models.14,17,18  Thus, our 
knock-in construct clearly has functional consequences in multiple cell types and stages of 
differentiation. (2) The lack of an HSC clonal advantage is consistent with results obtained from 
the transgenic CALR model where similar serial competitive transplants were performed (Fig 4c 
in Shide et al18).  (3) In homozygous mice, which have double the dose of the mutant allele, we 
still see no clonal advantage in secondary transplant recipients.  This is inconsistent with the 
concept that a 32% decrease in mutant transcript levels is responsible for the lack of an HSC 
repopulation advantage. (4) Our results demonstrate that several mutant CALR expression 
constructs (which are completely different from our knock-in construct; supplemental Fig. 2F) also 
give rise to lower transcript levels compared to WT controls.  In addition, the transcript levels of 
mutant CALR in the transgenic model are reported to be 64% of those of WT levels (Fig 3B in 
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Shide et al18).  Together, these data indicate that lower levels of mutant CALR transcript are not 
specific to the targeting construct for our knock-in mice and may represent altered stability 
associated with the novel 3’ sequence in mice.  It remains to be seen if lower mutant CALR mRNA 
levels are also present in patient samples. 
 
It is informative to compare the consequences of CALR and JAK2 mutations on HSCs.  CALRdel/+ 
mice displayed an increased number of phenotypic HSCs, but whole bone marrow serial 
transplantation experiments showed no functional alteration in competitive repopulation ability.  
Across several reported heterozygous JAK2V617F knock-in mouse models, phenotypic HSC 
frequency was variable, with some models having increased HSC numbers and others reporting a 
reduction.20,35,52,53  Nevertheless, where secondary transplants were performed, none of these 
models had a competitive self-renewal advantage compared to WT cells and, if anything, there 
was a functional decline in repopulating ability for JAK2V617F/+ cells in secondary 
recipients.20,24,35,54   In vitro, single E-SLAM HSCs from CALRdel/+ mice entered cell division 
earlier and produced substantially larger clones (3 fold increase in size) but did not display aberrant 
differentiation characteristics compared with their wild-type counterparts.  In contrast, single 
HSCs from heterozygous JAK2 mice did not show changes in early cell divisional kinetics but did 
give rise to larger, more differentiated clones. Notably, these clones contained increased lineage 
positive cells and reduced stem/progenitor (LSK) cells.20  Thus, while both mutant JAK2 and 
CALR can drive a myeloproliferative phenotype, their HSCs have distinct features both in vivo 
and in vitro, suggesting differences in downstream signaling pathways and in mechanisms of 
clonal expansion.    
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Taken together, our results support the concept that ET consists of biologically distinct entities 
associated with different mutations. It seems likely that it will become increasingly important to 
subclassify MPNs on the basis of their underlying causal mutations instead of relying on their 
phenotypic consequences (e.g. levels of hematocrit or megakaryocytic morphology).  Recent 
results suggest that the different consequences of CALR and JAK2 mutations reflect, at least in 
part, differential interaction of mutant CALR and JAK2 with the homodimeric cytokine receptors 
EPOR, THPO receptor and GCSFR, with mutant CALR preferentially binding to and activating 
THPO receptor.14,15  Our mouse model provides a powerful tool to further dissect the mechanisms 
by which mutant CALR contributes to MPN pathogenesis.  
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Figure 1.  Generation of a conditional humanized mutant CALR knock-in mouse model. (A) 
Diagrams showing the endogenous mouse CALR gene locus (CALR+), the targeting construct, the 
targeted conditional knock-in allele (CALRfl) and the recombined allele (CALRdel) following Cre 
recombination to remove the PGKNeopAstop cassette. The recombined allele is designed to carry 
the mouse CALR genomic region including mouse exons 1-7 followed by the 5’ part of mouse 
exon 8 fused to the 3’ part of the mutant human CALR cDNA sequence (orange).  LoxP sites are 
indicated by red arrows.  (B) Amino acid alignment of wild type and mutant calreticulin proteins.  
There is a 94% identity between the entire amino acid sequences of human and mouse proteins; 
alignments show amino acid 343 to the C-terminus of human mutant CALR and the designed 
humanized mutant CALR knock-in product (top panel) and the predicted product if the 
corresponding 52bp region is deleted in the mouse CALR gene.  Alignment was performed using 
an online program (www.expasy.org). Sites of the mouse/human junction and the 52bp deletion 
are indicated. (C) Diagram showing location of the primers for PCR genotyping.  (D) 
Characterization of ES cell targeting.  PCR performed on genomic DNA from ES clones (lanes 1-
5) using primers F and R shown in (C). The ES clone in lane 5 is correctly targeted. M; DNA size 
marker.  (E) Characterization of Cre/LoxP mediated recombination of targeted ES cells.  PCR was 
performed on genomic DNA from ES cells upon Cre recombinase expression using primers F and 
R shown in (C).  M, DNA marker; fl/+, targeted ES clone; +/+, wild type ES clones; lanes 1-2, Cre 
recombined ES clones. (F) Sequencing traces of RT-PCR product showing correct humanized 
mutant CALR expression with the 52bp deletion indicated (52bp del).  RT-PCR was performed on 
total RNA from an ES clone that was Cre recombined and the PCR product was cloned and 
sequenced. 
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Figure 2.  CALRdel/+ mice develop a myeloproliferative disease.  (A) Time course of blood 
parameters of CALRdel/+ and control mice showing significantly increased platelets, normal 
hematocrit and hemoglobin.  A mildly elevated white blood cell count is shown and is only seen 
in some cohorts. The CALRdel/+ mice were CALRfl/+ Mx1Cre+ and the littermate control mice 
CALR+/+ were CALRfl/+ Mx1Cre– or CALR+/+ Mx1Cre+. * P < 0.05; ** P < 0.01; *** P < 0.001; 
mean ± SEM are shown.  (B) Histological analysis showing megakaryocytic hyperplasia with 
increased clustering and hyperlobated nuclei without fibrosis.  H&E staining was performed on 
bone marrow (left panel) from mice at 3-4 months after pIpC injection; bone marrow staining for 
reticulin (middle panel) showing no fibrosis and H&E staining of spleen (right panel) showing 
normal splenic architecture.  (C) CALRdel/+ mice show increased megakaryocyte colonies.  Bar 
graphs showing significantly increased number of CFU-MK colonies in bone marrow.  CFU-MK 
assay was performed in media with or without TPO. (D) CALRdel/+ mice show increased 
megakaryocytes.  Flow cytometry was performed to assess the frequency of bone marrow 
megakaryocytes (MK, CD41+CD42+ or CD41+CD61+).  (E) CALRdel/+ mice show reduced 
erythroblasts in bone marrow.  Flow cytometry was performed to assess the frequency of 
erythroblasts (CD71+Ter119+).  * P < 0.05; ** P < 0.01; data are shown as mean ± SEM.  
 
Figure 3.  Thrombocytosis in CALRdel/+ mice is transplantable.  (A) Plasma THPO level is not 
significantly altered in CALRdel/+ mice.  (B) Donor chimerism is comparable in the primary non-
competitive bone marrow transplants.  Bone marrow cells from CALRdel/+ or control mice (2 x 106 
per recipient) were transplanted into irradiated (2 x 550 rads) CD45.1 C56BL/6 recipients 
respectively.  Donor chimerism in peripheral blood was analyzed using flow cytometry with 
CD45.1 and CD45.2 antibodies and are derived as percentage of CD45.2-positive cells in whole 
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nucleated blood.  (C) Time course of blood counts showing significantly increased platelet counts 
in the recipients of CALRdel/+ bone marrow.  * P <0.05; ** P <0.01; *** P <0.001; data are shown 
as mean ± SEM.  (D) Time course of blood counts showing significantly increased platelet counts 
in the secondary transplant recipients of CALRdel/+ bone marrow.  Bone marrow cells from the 
primary recipients of CALRdel/+ or control mice bone marrow (5 x 106 per recipient) were 
transplanted into irradiated (1 x 400 rads) KitW41/W41 (CD45.1) recipients respectively.  * P < 0.05; 
data are shown as mean ± SEM.  (E) Donor chimerism is comparable in the secondary non-
competitive bone marrow transplants.  Donor chimerism in peripheral blood was analyzed using 
flow cytometry as above.  
 
Figure 4.   Mutant CALR increases phenotypic HSCs with altered behavior in vitro but no 
self-renewal advantage in vivo.  (A) CALRdel/+ mice show increased frequency of HSCs in the 
bone marrow.  Flow cytometry was performed on bone marrow from mice at 3-4 months post 
pIpC injection and HSC is defined as lineage-Sca-1+c-Kit+CD150+CD48-. **, P<0.01; data are 
shown as mean ± SEM.  (B) CALRdel/+ E-SLAM HSCs have a significantly higher cloning 
efficiency than wild-type E-SLAM HSCs. Single E-SLAMs were defined as successfully forming 
a clone if assayed to have more than 50 cells at day 7 as assessed by flow cytometry.  Both CALR+/+ 
and CALRdel/+ represent 72 individual E-SLAMs HSCs from 3 independent experiments; **, 
P<0.01; p-value was calculated from a chi-squared test.  (C) E-SLAM HSCs from CALRdel/+ mice 
exhibit early cell division in a single cell in vitro assay.  Line graphs showing significantly higher 
proportion of E-SLAM HSCs completed first division during the 4 days of single cell in vitro 
analysis.  *, P<0.01; p-value was calculated from a chi-squared test; three independent 
experiments were performed.  (D) E-SLAM HSCs from CALRdel/+ mice form larger clones in vitro.  
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After 7 days in culture, E-SLAM clones (irrespective of size) were analyzed using flow cytometry 
and the average number of cells per clone was measured; *, P<0.01; data are shown as mean ± 
SEM.  (E) Bone marrow cells from CALRdel/+ mice show similar repopulating capacity in 
peripheral blood of primary competitive transplants.  Donor repopulation was assessed using flow 
cytometry of nucleated peripheral blood with antibodies for CD45.1 and CD45.2 to distinguish 
donor origin; Ly6g and Mac1 for myeloid; and B220 and CD3e for lymphoid lineages.  
Competitive repopulating ability is presented as the percentage of repopulated cells derived from 
test donor cells among the total number of donor-derived cells (i.e. test/(test + competitor)).  Bar 
graphs showing bone marrow cells from CALRdel/+ mice exhibit comparable repopulating capacity 
to both myeloid and lymphoid cells in peripheral blood. Mean ± SEM are shown.  (F) CALRdel/+ 
bone marrow primary recipients show similar frequency of donor derived E-SLAM HSCs 
compared to the control recipient mice.  Flow cytometry was performed using antibodies for 
CD45.1 and CD45.2 together with antibodies for E-SLAM HSC markers.  Data are shown as mean 
± SEM.  (G) Bone marrow cells from CALRdel/+ mice show similar repopulating capacity in bone 
marrow of primary competitive transplants.  Primary recipients were culled 4 months after 
transplantation and flow cytometry was performed as above to assess donor competitive 
repopulating ability in the bone marrow.  Bar graphs showing bone marrow cells from CALRdel/+ 
mice exhibit comparable repopulating capacity to both myeloid and lymphoid lineages in the bone 
marrow of the primary recipients; data are shown as mean ± SEM.  (H) Bone marrow cells from 
CALRdel/+ mice show similar repopulating capacity in secondary competitive transplants.  Donor 
repopulation was assessed using flow cytometry of peripheral blood as in (E).  Bar graphs showing 
comparable repopulating capacity to multiple lineages in peripheral blood in the secondary 
competitive transplantation recipients; data are shown as mean ± SEM. 
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Figure 5.  CALRdel/del mice develop an extreme myeloproliferative disease with myelofibrosis.  
(A) CALRdel/del mice develop marked thrombocytosis.  Bar graphs showing significantly increased 
platelets, elevated WBC counts and reduced hematocrit in CALRdel/del mice at 3-4 months post 
pIpC.  The CALRdel/del mice were CALRfl/fl Mx1Cre+ and CALRdel/+ mice were CALRfl/+ Mx1Cre+ 
and the control mice (CALRwt/+) were CALRfl/+ Mx1Cre– or CALR+/+ Mx1Cre+. *, P<0.01; ***, 
P<0.001; data are shown as mean ± SEM.  (B) CALRdel/del mice show splenomegaly.  (C) 
CALRdel/del mice show striking megakaryocytic hyperplasia.  Tissues from mice at 7-8 months 
post pIpC were taken for histological analysis.  H&E staining of bone marrow (left panel) showing 
almost complete effacement of normal haematopoiesis by megakaryocytes, displaying nuclear 
atypia in CALRdel/del mice;  silver staining for reticulin (middle panel) showing bone marrow 
fibrosis in CALRdel/del mice;  H&E staining of spleen (right panel) showing destruction of splenic 
architecture in CALRdel/del mice.  (D) CALRdel/del mice show markedly increased frequencies of 
HSCs.  Flow cytometry was performed and HSCs were defined as Lin-cKit+Sca1+CD150+CD48-.  
(E) CALRdel/del mice show markedly increased frequencies of megakaryocytic progenitors (MkP, 
Lin-cKit+Sca1-CD150+CD41+).  (F) CALRdel/del mice show markedly increased frequencies of 
myeloid progenitors in spleen.  Flow cytometry was performed and myeloid progenitors were 
defined as Lin-cKit+Sca1- population.  (G) CALRdel/del mice show significantly reduced numbers 
of erythroblasts.   Flow cytometry was performed and erythroblasts were defined as 
CD71+Ter119+. *, P<0.05; **, P<0.01; data are shown as mean ± SEM.  
Figure 6.  Mutant CALR homozygosity results in a transplantable extreme thrombocytosis 
but does not confer competitive repopulating advantage in serial transplants.   (A) Donor 
chimerism is comparable in the primary non-competitive bone marrow transplants.  Bone marrow 
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cells from CALRdel/del or control mice at 7-8 months post pIpC (2 x 106 per recipient) were 
transplanted into irradiated (1 x 400 rads) KitW41/W41 C56BL/6 recipients (CD45.1+) respectively.  
Bar graphs show donor chimerism in peripheral blood which was analyzed using flow cytometry 
with CD45.1 and CD45.2 antibodies and is derived as percentage of CD45.2-positive cells in 
whole nucleated blood.  Time course of blood counts are shown and significantly increased platelet 
counts were seen in the recipients of CALRdel/+ bone marrow.  * P <0.05; ** P <0.01; *** P 
<0.001; data are shown as mean ± SEM.  (B) Bone marrow cells from CALRdel/del mice show 
similar repopulating capacity in peripheral blood of primary competitive transplants.  Donor 
repopulation was assessed using flow cytometry detailed as in Figure 4E; data are shown as mean 
± SEM.  (C) Bone marrow cells from CALRdel/del mice show similar repopulating capacity in 
secondary competitive transplants.  Donor repopulation was assessed using flow cytometry of 
peripheral blood as in Figure 4E and bar graphs showing comparable repopulating capacity to 
multiple lineages in peripheral blood in the secondary competitive transplantation recipients are 
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